Jari Karlson, the Chief Financial Officer of the Orion Group and member of the Executive Management Board of the Orion Group has announced that he will step down from his position at Orion as of 30 April 2024 and that he will retire. He has worked in his current position since 2002.
Orion has started the recruiting process of the successor of Jari Karlson. Karlson will continue in his current position and as a member of the Executive Management Board of the Orion Group until 30 April 2024.
| Liisa Hurme|
President and CEO
| Olli Huotari|
SVP, Corporate Functions
Liisa Hurme, President and CEO
tel. +358 10 426 2874
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.